Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725686 · ClinicalTrials.gov registry record · Phase 1
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
A Phase 1 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00725686 is a Phase 1 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT00725686, a Phase 1 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
Interventions
- DRUG PF-04523655
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725686
The ClinicalTrials.gov registry entry for NCT00725686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04523655 is the first listed.
NCT00725686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00725686 about?
NCT00725686 is a clinical study titled "Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)". The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
What is the current status of trial NCT00725686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2007-02. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00725686?
The interventions under investigation include: PF-04523655 (DRUG).
Who is sponsoring clinical trial NCT00725686?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.